In this insightful interview, Dr Abizaid discusses the findings and implications of DESyne BDS Plus study. The conversation delves into the study's design, key results at 12-month follow-up and future potential impact on clinical practice.

Balancing ischaemic and bleeding risk with oral anti-thrombotic drugs remains a significant clinical challenge, especially in patients who are at high thrombotic risk and high bleeding risk. 12-month results from DESyne BDS Plus RCT demonstrate the safety and effectiveness of site specific anti-thrombotic drug therapy (TRx) with significantly lower TLF rate (2.1% vs. 9.3%, p=0.030) vs the contemporary DES group in complex patients.¹ The interview highlights how the RCT findings could potentially impact patient outcomes post-intervention and influence clinical practice.

References:

1. DESyne BDS Plus Trial 12-month Outcomes. EuroPCR 2024.